Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Samuel C. Blackman"'
Autor:
Cornelis M. van Tilburg, Lindsay B. Kilburn, Sébastien Perreault, Rene Schmidt, Amedeo A. Azizi, Ofelia Cruz-Martínez, Michal Zápotocký, Katrin Scheinemann, Antoinette Y. N. Schouten-van Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driever, Shivaram Avula, David S. Ziegler, David Capper, Arend Koch, Felix Sahm, Jiaheng Qiu, Li-Pen Tsao, Samuel C. Blackman, Peter Manley, Till Milde, Ruth Witt, David T. W. Jones, Darren Hargrave, Olaf Witt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549::BRAF fusions and
Externí odkaz:
https://doaj.org/article/6042d3662e6a4c2d9fc8d41531bad22c
Autor:
Richard F. Kefford, Daniele Ouellet, Bo Ma, Peter Lebowitz, C. Martin Curtis, Samuel C. Blackman, Steven J. O'Day, Melvin T. Chin, Anna Pavlick, Michael Millward, Jeffrey R. Infante, Omid Hamid, Michael P. Brown, H.-Tobias Arkenau, Kevin B. Kim, Razelle Kurzrock, Georgina V. Long, Gerald S. Falchook
Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose selection in the first-in-human study of dabrafenib, including phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ced035f5a9c3adb4d6d3ba6e5392e18d
https://doi.org/10.1158/1078-0432.c.6522927.v1
https://doi.org/10.1158/1078-0432.c.6522927.v1
Autor:
Richard F. Kefford, Daniele Ouellet, Bo Ma, Peter Lebowitz, C. Martin Curtis, Samuel C. Blackman, Steven J. O'Day, Melvin T. Chin, Anna Pavlick, Michael Millward, Jeffrey R. Infante, Omid Hamid, Michael P. Brown, H.-Tobias Arkenau, Kevin B. Kim, Razelle Kurzrock, Georgina V. Long, Gerald S. Falchook
Table S1. Treatment-related adverse events of {greater than or equal to} grade 2 reported in at least 5% of patients by dose (3); Table S2. Summary of plasma dabrafenib pharmacokinetic parameters after single-dose administration of dabrafenib gelatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6954178cfdd02cc0e6fa2fbb6ada516a
https://doi.org/10.1158/1078-0432.22455123
https://doi.org/10.1158/1078-0432.22455123
Autor:
Joe McDonough, G. Lesa, Franca Ligas, Miguel Rivera, Ira Jacobs, Andrew D.J. Pearson, Malcolm A. Smith, Maureen Hattersley, Dominik Karres, Aundrietta D. Duncan, Nada Jabado, Daniel D. De Carvalho, Koen Norga, Peter C. Adamson, Donna Ludwinski, Gregory H. Reaman, Brian Gadbaw, Elizabeth Fox, Samuel C. Blackman, Mark W. Kieran, Gilles Vassal, Christian Baumann, Vickie Buenger, Delphine Heenen, Scott A. Armstrong, Michael J. Kelly, Amy Barone, Adrian Senderowicz, Franck Bourdeaut, Martha Donoghue, Tilmann Taube, Peter T.C. Ho, Lynley V. Marshall, Patrick A. Brown, Michael L. Meyers, Kimberly Stegmaier, Zariana Nikolova, Susan L. Weiner
Publikováno v:
European Journal of Cancer. 139:135-148
The fifth multistakeholder Paediatric Strategy Forum focussed on epigenetic modifier therapies for children and adolescents with cancer. As most mutations in paediatric malignancies influence chromatin-associated proteins or transcription and paediat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c517dea500b05206723e5227a0df2155
https://doi.org/10.1016/j.ejca.2020.08.014
https://doi.org/10.1016/j.ejca.2020.08.014
Autor:
Daniel B Landi, David S. Ziegler, Andrea Flynn Franson, Patricia Ann Baxter, Sarah Leary, Valérie Larouche, Angela Jae Waanders, Jasper Van der Lugt, Geoffrey Brian McCowage, Francois Doz, Nada Jabado, Elisabetta Schiavello, Michal Zapotocky, Izzy Cornelio, Samuel C Blackman, Daniel Da Costa, Michael Craig Cox, Olaf Witt, Lindsay Baker Kilburn, Jordan R. Hansford
Publikováno v:
Journal of Clinical Oncology. 40:TPS10062-TPS10062
TPS10062 Background: RAF gene fusions ( BRAF and RAF1) and BRAF V600E mutations are oncogenic drivers found on a mutually exclusive basis in most pediatric low-grade gliomas (LGGs). In addition, RAF fusions ( BRAF and RAF1) have also been identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e008124ee3150bd43a94227604f46d
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10062
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10062
Publikováno v:
Neuro Oncol
BACKGROUND Calculated from a diffusion-weight image (DWI), the apparent diffusion coefficient (ADC) is a quantitative measure that reflects observed net movement of water and correlates to tumor cellularity. We examine the changes in ADC values in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9eff29b6d1323a870df86d44511622
https://europepmc.org/articles/PMC7650471/
https://europepmc.org/articles/PMC7650471/
Publikováno v:
Neuro-Oncology
BACKGROUND Apparent diffusion coefficient (ADC) is a quantitative measure reflecting observed net movement of water calculated from a diffusion-weighted image (DWI), correlating with tumor cellularity. The higher cellularity of high-grade gliomas res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c9c2cb0a4a2e2640127c94d8afb12c
http://europepmc.org/articles/PMC7715396
http://europepmc.org/articles/PMC7715396
Autor:
Donald A. Bergstrom, Luiz M Camargo, Andrey Loboda, Bo Wei, Jeremy Hing, Sanjiv J. Shah, Eva M. Finney, Samuel C. Blackman, Radha Railkar, Amy Harman, Peter Strack, Tim Demuth, Gary A. Herman, Jared Lunceford, Keith Q. Tanis, James S. Hardwick, Joel A. Klappenbach, James Watters, Robert Iannone, Alexei A. Podtelezhnikov
Publikováno v:
Clinical Pharmacology & Therapeutics. 99:370-380
γ-Secretase mediates amyloid production in Alzheimer's disease (AD) and oncogenic activity of Notch. γ-Secretase inhibitors (GSIs) are thus of interest for AD and oncology. A peripheral biomarker of Notch activity would aid determination of the the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c928c8085458739b360786c67c6df537
https://doi.org/10.1002/cpt.335
https://doi.org/10.1002/cpt.335
Autor:
Mark E. Fleury, Gregory H. Reaman, Raleigh E. Malik, Samuel C. Blackman, Kenneth J. Cohen, Martha Donoghue, Gilles Vassal, Raphael Rousseau, Nita L. Seibel, Tahira Khan, Bouchra Benettaib, Mark Stewart
Publikováno v:
Therapeutic innovationregulatory science. 53(2)
Although outcomes for children with cancer have significantly improved over the past 40 years, there has been little progress in the treatment of some pediatric cancers, particularly when advanced. Additionally, clinical trial options and availabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc8516f06743dc51eda45854e8715d15
https://pubmed.ncbi.nlm.nih.gov/29759018
https://pubmed.ncbi.nlm.nih.gov/29759018
Autor:
K. B. Kim, Melvin Chin, B. Ma, Anna C. Pavlick, Omid Hamid, Daniele Ouellet, Michael Millward, C. M. Curtis, Georgina V. Long, Samuel C. Blackman, H.T. Arkenau, Gerald S. Falchook, Steven J. O'Day, Michael P. Brown, P. Lebowitz, Razelle Kurzrock, Richard F. Kefford, J. R. Infante
Publikováno v:
Clinical Cancer Research. 20:4449-4458
Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose selection in the first-in-human study of dabrafenib, including phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67741b2f4242b071ef9a3b26585aacc6
https://doi.org/10.1158/1078-0432.ccr-14-0887
https://doi.org/10.1158/1078-0432.ccr-14-0887